SCHEDULE 13G/A: Venrock Healthcare Capital Partners Group Discloses 4.5% Stake in ORIC Pharmaceuticals
Beneficial Ownership Report
A group of Venrock Healthcare Capital Partners entities and individuals have filed an amended Schedule 13G, reporting a collective beneficial ownership of 4.5% in ORIC Pharmaceuticals, Inc. as of March 31, 2025.
Summary
- Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
- The filing indicates that as of March 31, 2025, the Reporting Persons collectively beneficially own 3,182,527 shares of ORIC Pharmaceuticals, Inc. Common Stock.
- This aggregate ownership represents 4.5% of ORIC Pharmaceuticals' outstanding Common Stock.
- The percentage is calculated based on 71,026,825 shares of Common Stock outstanding as of February 4, 2025, as reported in ORIC Pharmaceuticals' Annual Report on Form 10-K filed on February 18, 2025.
- The ownership is distributed among the entities as follows: 473,423 shares by VHCP III, 47,364 shares by VHCP Co-Investment III, and 2,661,740 shares by VHCP EG.
- The Reporting Persons have shared voting and shared dispositive power over all 3,182,527 shares.
- The securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook. It is a neutral regulatory filing.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding ORIC Pharmaceuticals' future performance or strategic direction.
Industry Context
This filing is a standard disclosure by an institutional investor group, Venrock Healthcare Capital Partners, indicating their significant but non-controlling stake in ORIC Pharmaceuticals, a biotechnology company. Such filings provide transparency into major shareholder positions, which can be of interest to other investors tracking institutional confidence or potential activist stakes, though in this case, the filing explicitly states the stake is not for control purposes.
Related Party Transactions
- The Reporting Persons, including various Venrock Healthcare Capital Partners entities and their voting members (Nimish Shah and Bong Koh), are considered a group for the purposes of this Schedule 13G, indicating a coordinated ownership and reporting structure.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence investor sentiment and potentially signal confidence in the company, although the filing explicitly states the stake is not for control purposes.
- Investment Professionals: Offers data points for tracking institutional ownership and potential shifts in major shareholder bases.
Key Dates
| Date | Description |
|---|---|
| 2024-02-01 | Date of previous Schedule 13G filing where Power of Attorney for Nimish Shah and Bong Koh were incorporated by reference. |
| 2025-02-04 | Date as of which 71,026,825 shares of ORIC Pharmaceuticals' Common Stock were outstanding, as reported in the Issuer's 10-K. |
| 2025-02-18 | Date ORIC Pharmaceuticals filed its Annual Report on Form 10-K with the SEC. |
| 2025-03-31 | Date of event which requires filing of this Schedule 13G Amendment No. 1, reflecting the beneficial ownership stake. |
| 2025-05-15 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
ORIC Pharmaceuticals, Venrock Healthcare Capital Partners, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.